You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國抗體(3681.HK)漲8% SN1011臨牀試驗獲進展
格隆匯 11-15 15:48
格隆匯11月15日丨上市後連跌3日的中國抗體-B(3681.HK)今日有明顯上漲,現報4.78港元,漲8.14%,暫成交4663萬港元,最新總市值48.1億港元。
公司昨晚發佈主要產品之一SN1011的臨牀試驗進展稱,關於SN1011在澳洲進行免疫性疾病的I期臨牀試驗,截至2019年11月13日,已有24名受試者分三隊列完成給藥,尚無嚴重不良事件報告,當前安全性符合預期。公司預計下週開始為第四隊列受試者給藥。
公告稱,SN1011是公司的第三代可逆共價BTK抑制劑,其設計在治療類風濕關節炎、天皰瘡及系統性紅斑狼瘡長期用藥方面具備更高選擇性及更卓越療效。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account